BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18650353)

  • 1. Metronidazole resistance in Clostridium difficile is heterogeneous.
    Peláez T; Cercenado E; Alcalá L; Marín M; Martín-López A; Martínez-Alarcón J; Catalán P; Sánchez-Somolinos M; Bouza E
    J Clin Microbiol; 2008 Sep; 46(9):3028-32. PubMed ID: 18650353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.
    Barbut F; Decré D; Burghoffer B; Lesage D; Delisle F; Lalande V; Delmée M; Avesani V; Sano N; Coudert C; Petit JC
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2607-11. PubMed ID: 10543736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolone resistance and Clostridium difficile, Germany.
    Zaiss NH; Witte W; Nübel U
    Emerg Infect Dis; 2010 Apr; 16(4):675-7. PubMed ID: 20350385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran.
    Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M
    Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Plasmid-Mediated Resistance to Metronidazole in Clostridioides difficile from River Water.
    Cizek A; Masarikova M; Mares J; Brajerova M; Krutova M
    Microbiol Spectr; 2022 Aug; 10(4):e0080622. PubMed ID: 35950844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of reduced susceptibility to metronidazole in Clostridium difficile.
    Baines SD; O'Connor R; Freeman J; Fawley WN; Harmanus C; Mastrantonio P; Kuijper EJ; Wilcox MH
    J Antimicrob Chemother; 2008 Nov; 62(5):1046-52. PubMed ID: 18693234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.
    Aspevall O; Lundberg A; Burman LG; Akerlund T; Svenungsson B
    Antimicrob Agents Chemother; 2006 May; 50(5):1890-2. PubMed ID: 16641471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emergence of metronidazole and vancomycin reduced susceptibility in Clostridium difficile isolates in Iran.
    Kouhsari E; Douraghi M; Krutova M; Fakhre Yaseri H; Talebi M; Baseri Z; Moqarabzadeh V; Sholeh M; Amirmozafari N
    J Glob Antimicrob Resist; 2019 Sep; 18():28-33. PubMed ID: 30703583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes.
    Moura I; Spigaglia P; Barbanti F; Mastrantonio P
    J Antimicrob Chemother; 2013 Feb; 68(2):362-5. PubMed ID: 23104495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants.
    Gal M; Brazier JS
    J Antimicrob Chemother; 2004 Jul; 54(1):109-16. PubMed ID: 15190033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary analysis of a nontoxigenic Clostridium difficile strain with stable resistance to metronidazole.
    Moura I; Monot M; Tani C; Spigaglia P; Barbanti F; Norais N; Dupuy B; Bouza E; Mastrantonio P
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4957-60. PubMed ID: 24913157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversity of Circulating
    Martínez-Meléndez A; Tijerina-Rodríguez L; Collins N; Baines SD; Morfin-Otero R; Camacho-Ortíz A; Villarreal-Treviño L; Garza-González E
    Microb Drug Resist; 2021 Dec; 27(12):1672-1676. PubMed ID: 34037477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of Clostridium difficile from dogs with digestive disorders, including stable metronidazole-resistant strains.
    Orden C; Blanco JL; Álvarez-Pérez S; Garcia-Sancho M; Rodriguez-Franco F; Sainz A; Villaescusa A; Harmanus C; Kuijper E; Garcia ME
    Anaerobe; 2017 Feb; 43():78-81. PubMed ID: 27965048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of linezolid against Clostridium difficile.
    Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
    Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.
    Huhulescu S; Sagel U; Fiedler A; Pecavar V; Blaschitz M; Wewalka G; Allerberger F; Indra A
    J Med Microbiol; 2011 Aug; 60(Pt 8):1206-1212. PubMed ID: 21292853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
    Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.
    Wong SS; Woo PC; Luk WK; Yuen KY
    Diagn Microbiol Infect Dis; 1999 May; 34(1):1-6. PubMed ID: 10342100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile.
    Boekhoud IM; Sidorov I; Nooij S; Harmanus C; Bos-Sanders IMJG; Viprey V; Spittal W; Clark E; Davies K; Freeman J; Kuijper EJ; Smits WK;
    J Antimicrob Chemother; 2021 Jun; 76(7):1731-1740. PubMed ID: 33876817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.